Intensification of type 2 diabetes therapy: new accents of traditional approaches

• Galina V. Semikova
• Yuriy Sh. Khalimov

Abstract

Type 2 diabetes mellitus (T2DM) is a common disease, the consequences and complications of which lead to death of thousands. Chronic hyperglycemia significantly increases cardiovascular risk. Mortality from myocardial infarction and cerebral blood flow disorders in patients with T2DM is several times higher than the population average. Thus, controlling hyperglycemia appears to be a key aspect of managing the complications of T2DM. Most patients do not achieve individual goals of glycemic control on monotherapy, as a result of which early intensification of hypoglycemic therapy is currently preferred. An important clinical task is the timely administration of effective, safe and affordable second-line hypoglycemic therapy.

Keywords:type 2 diabetes mellitus; therapy intensification; cardiovascular complications; gliclazide modified release

References

1. Nauck M.A., Quast D.R., Wefers J., Meier J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021; 46: 101102.

2. Dedov I.I., Shestakova M.V. The phenomenon of «metabolic memory» in predicting the risk of vascular complications in diabetes mellitus. Terapevticheskiy arkhiv [Therapeutic Archive]. 2015; (10): 4–10. (in Russian)

3. Nathan D.M.; for the DCCT/EDIC Research group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014; 37: 9–16.

4. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (7258): 405–12.

5. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577–89.

6. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 937–52.

7. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein H.C., Miller M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358 (24): 2545–59. DOI: https://doi.org/10.1056/NEJMoa0802743

8. Duckworth W., Abraira C., Moritz T., et al.; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129–39.

9. ADVANCE Collaborative Group; Patel A., MacMahon S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358 (24): 2560–72. DOI: https://doi.org/10.1056/NEJMoa0802987

10. Algorithms for specialized medical care for patients with diabetes mellitus. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 11th issue. Moscow, 2023. DOI: https://doi.org/10.14341/DM13042 (in Russian)

11. Corgnali M., Piconi L., Ihnat M., Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic «memory» induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev. 2008; 24: 301–9.

12. Khunti K., Seidu S. Therapeutic inertia and the legacy of dysglycemia on the microvascular and macrovascular complications of diabetes. Diabetes Care. 2019; 42 (3): 349–51. DOI: https://doi.org/10.2337/dci18-0030

13. Zafar A., Stone M.A., Davies M.J., Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015; 32 (3): 407–13. DOI: https://doi.org/10.1111/dme.12592

14. Osataphan S., Chalermchai T., Ngaosuwan K. Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: a retrospective cohort study. J Diabetes. 2017; 9 (3): 267–74. DOI: https://doi.org/10.1111/1753-0407.12410 Epub 2016 Jul 12. PMID: 27092709.

15. Kosiborod M., Cavender M.A., Fu A.Z., et al.; CVD-REAL Investigators and Study Group. Response by Kosiborod et al to letters regarding article «Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)». Circulation. 2018; 137 (9): 989–91. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.031847 PMID: 29483180.

16. Matthews D.R., Paldánius P.M., Proot P., Chiang Y., Stumvoll M., Del Prato S.; VERIFY Study Group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394 (10 208): 1519–29. DOI: https://doi.org/10.1016/S0140-6736(19)32131-2 Epub 2019 Sep 18. PMID: 31542292.

17. Khunti K., Godec T.R., Medina J., et al. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: retrospective data for 10 256 individuals from the United Kingdom and Germany. Diabetes Obes Metab. 2018; 20 (2): 389–99. DOI: https://doi.org/10.1111/dom.13083 Epub 2017 Sep 28. PMID: 28817227; PMCID: PMC 5813147.

18. Zaccardi F., Jacquot E., Cortese V., et al. Comparative effectiveness of gliclazide modified release vs sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2020; 22 (12): 2417–26. https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14169

19. Tayek J. SUR receptor activity vs incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008; 10 (11): 1128–30. DOI: https://doi.org/10.1111/j.1463-1326.2008.00928.x

20. Al Sifri S., Basiounny A., Echtay A., et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65 (11): 1132–40. DOI: https://doi.org/10.1111/j.1742-1241.2011.02797.x

21. Simpson S.H., Lee J., Choi S., Vandermeer B., Abdelmoneim A.S., Featherstone T.R. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015; 3 (1): 43–51.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)